Alterity Therapeutics to Present New Data at the Upcoming Am

– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference –

Related Keywords

Colorado , United States , Australia , Melbourne , Victoria , Denver , San Francisco , California , Americans , American , Remy Bernarda , Hannah Howlett , Danielo Claassen , David Stamler , Margaret Bradbury , Daniel Claassen , Alterity Therapeutics , Nonclinical Development , American Academy Of Neurology , Vanderbilt University , National Institute Of Health , International Conference , Nasdaq , Parkinson Foundation , Vanderbilt University Medical Center , European Commission , Positive Efficacy Data , Primate Model , Baseline Biomarker Data , American Academy , Chief Executive Officer , Novel Inhibitor , Synuclein Aggregation , Multiple System Atrophy , Plight Chain , Clinical Progression , Early Multiple System , Vanderbilt University Medical , Clinical Phase Small Molecule , Moderate Affinity , Disease Model , Vice President , System Atrophy , Neurological Disorders , Disease Information Page , Multiple System , Media Contacts , Region ,